Corbus Pharmaceuticals Holdings Inc(CRBP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -6.18 | Insider Own | 10.22% | Shs Outstand | 18.7M | Perf Week | 4.2% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | 0.92% | Insider Trans | -1.21% | Shs Float | 17.4M | Perf Month | -33.44% |
| Enterprise Value | -0.03B | PEG | - | EPS next Q | -1.27 | Inst Own | 72.5% | Short Float | 15.64% | Perf Quarter | -52.69% |
| Income | -0.10B | P/S | - | EPS this Y | 5.12% | Inst Trans | 4.19% | Short Ratio | 3.05 | Perf Half Y | -59.03% |
| Sales | 0.00B | P/B | 0.77 | EPS next 5Y | 1.15% | ROA | -80.85% | Short Interest | 2.71M | Perf YTD | -48.16% |
| Book/sh | 5.48 | P/C | 0.69 | EPS past 3/5Y | 16.56% 32.7% | ROE | -95.58% | 52W High | -75.52% ($17.24) | Perf Year | -74.33% |
| Cash/sh | 6.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -96.59% | 52W Low | 9.04% ($3.87) | Perf 3Y | -22.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -29.66% | Gross Margin | - | Volatility(W/M) | 5.09% 7.78% | Perf 5Y | -85.93% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.38 | Perf 10Y | -97.32% |
| Dividend Ex-Date | - | Quick Ratio | 5.71 | EPS Q/Q | -25.12% | Profit Margin | - | RSI (14) | 25.58 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.71 | Sales Q/Q | - | SMA20 | -9.5% ($4.66) | Beta | 2.75 | Target Price | $33.12 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/6 | SMA50 | -41.18% ($7.17) | Rel Volume | 2.61 | Prev Close | $4.22 |
| Employees | 36 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -43.79% - | SMA200 | -51.05% ($8.62) | Avg Volume(3M) | 0.89M | Price | $4.22 |
| IPO | 2014/10/27 | Option/Short | Yes/Yes | Trades | 4913 | Volume | 2,317,188 | Change | - |
🧬 This is a clinical-stage biotech company developing oncology and obesity therapeutics. Headquartered in Norwood, Massachusetts, it stands out for a diversified pipeline that includes both antibody-drug conjugate (ADC)-based oncology treatments and an oral obesity therapy candidate.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded more than usual. That is 261% of its average volume.
CRBP has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +5.1% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -85.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 72.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #375 of 595 in the industry
Based on market cap of $82M.
RLYB#372 Rallybio Corp $85M PER 3.5 
TNYA#373 Tenaya Therapeutics Inc $84M PER - 
RANI#374 Rani Therapeutics Holdings Inc $82M PER - CRBP#375 Corbus Pharmaceuticals Holdings Inc $82M PER - 
ATRA#376 Atara Biotherapeutics Inc $80M PER - 
FAQ
What kind of company is CRBP?
CRBP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CRBP?
The market cap of CRBP is approximately $82M, ranking 4,573 within its sector.
What is the 52-week high and low for CRBP?
CRBP has recorded a 52-week high of $17.24 and a low of $3.87.
